Scale of reach Sandoz Canada serves as a gateway to a broad patient base through its global generics and biosimilars portfolio, offering potential collaboration opportunities with Canadian healthcare providers and payer networks to expand access and drive volume.

Diverse portfolio With over 700 medicines spanning anti-infective, cardiovascular, diabetes, CNS, immunology, and oncology, there are multiple entry points for co-promotion, tender alignment, and market expansion in Canada.

Recent launches Upcoming and recent launches such as the ophthalmology biosimilar Enzeevu and anticipated generic semaglutide positions Sandoz Canada to pursue hospital and specialty channels, enabling targeted sales in ophthalmology and chronic disease management.

Strategic partnerships Existing collaborations (e.g., FSC packaging and Bio-Thera Solutions) indicate openness to ecosystem partnerships, suggesting opportunities for supply chain sustainability programs, packaging innovations, and co-commercialization with regional partners.

Recognition & leadership Award recognition for leadership and strong local presence signals a stable brand trust environment in pharmacies, physicians, and hospitals, making it conducive to upsell generic/biosimilar portfolios and long-term contract opportunities.